Based on the Northwest Biotherapeutics Inc stock forecast from 0 analysts, the average analyst target price for Northwest Biotherapeutics Inc is not available over the next 12 months. Northwest Biotherapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Northwest Biotherapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Northwest Biotherapeutics Inc’s stock price was USD 0.21. Northwest Biotherapeutics Inc’s stock price has changed by +10.53% over the past week, -16.00% over the past month and -58.17% over the last year.
No recent analyst target price found for Northwest Biotherapeutics Inc
No recent average analyst rating found for Northwest Biotherapeutics Inc
Company Overview Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Read Less
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient'...Read More
Frequently Asked Questions About Northwest Biotherapeutics Inc (NWBO) Stock
Stock Target Advisor's fundamental analysis for Northwest Biotherapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on NWBO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NWBO's stock to indicate what its average analyst target is.
NWBO stock's Price/Earning ratio is 81.98.
Our analysis grades NWBO stock's Price / Earning ratio at F. This means that NWBO stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this NWBO may be a overvalued for its sector.
The last closing price of NWBO's stock was USD 0.21.
The most recent market capitalization for NWBO is USD 0.29B.
Unfortunately we do not have enough analyst data on NWBO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Northwest Biotherapeutics Inc's stock.
As per our most recent records Northwest Biotherapeutics Inc has 0 Employees.
Northwest Biotherapeutics Inc's registered address is 4800 Montgomery Lane, Bethesda, MD, United States, 20814.
You can get more information about it from Northwest Biotherapeutics Inc's website at https://www.nwbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Northwest Biotherapeutics Inc (NWBO) Stock
Stock Target Advisor's fundamental analysis for Northwest Biotherapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on NWBO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NWBO's stock to indicate what its average analyst target is.
NWBO stock's Price/Earning ratio is 81.98.
Our analysis grades NWBO stock's Price / Earning ratio at F. This means that NWBO stock's Price/Earning ratio is above 91% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this NWBO may be a overvalued for its sector.
The last closing price of NWBO's stock was USD 0.21.
The most recent market capitalization for NWBO is USD 0.29B.
Unfortunately we do not have enough analyst data on NWBO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Northwest Biotherapeutics Inc's stock.
As per our most recent records Northwest Biotherapeutics Inc has 0 Employees.
Northwest Biotherapeutics Inc's registered address is 4800 Montgomery Lane, Bethesda, MD, United States, 20814.
You can get more information about it from Northwest Biotherapeutics Inc's website at https://www.nwbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NWBO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
